Phase II clinical trial results demonstrated: Body weight reduction of up to 2% at 48 weeks ( vs 2.1% placebo ) 83% of participants achieved 15% body weight loss at highest dose HbA1c reduction of up to 02% in Type 2 Diabetes participants ( vs 0% placebo ) Normalization of liver fat in 86% of participants with hepatic steatosis Reduction in systolic blood pressure averaging 6-8 mmHg Phase II findings are preliminary
Some influencers promote peptide stacks that combine BPC-157 with TB-500 to support connective tissue recovery
When Retatrutide activates these receptors, users experience reduced hunger, earlier feelings of fullness during meals, and decreased food cravings between meals
The FDA had already approved a pill to be used for treating diabetes, but the new development now allows doctors to prescribe the treatment for weight loss to adults with obesity or who are overweight with at least one weight-related comorbidity, such as a heart condition, the company said
Maybe you lost 20, 30, even 40 pounds